Increases glycolysis levels through regulated HSP90 expression levels, leading to lactate accumulation and acceleration of renal cell carcinoma development. The tumor-promoting effect of lovastatin is reversed by Shikonin (Huang et al., 2021). This evidence concerns the gene HSP90AB1 and hereditary clear cell renal cell carcinoma.